Suplatast tosilate, a new type of antiallergic agent, prevents the expression of airway hyperresponsiveness in guinea pigs

Taniguchi, Hajime; Togawa, Michinori; Ohwada, Katsuo; Kiniwa, Mamoru; Matsuura, Naosuke; Nagai, Hiroichi; Koda, Akihide

doi:10.1016/s0014-2999(96)00810-2

Cited by 19 publications

(11 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1), {2-[4-(3-ethoxy-2-hydroxypropoxy)-phenylcarbamoyl]-ethyl} dimethylsulforium p-toluenesulfonate, is an anti-allergic drug (Ushio and Yamamoto, 1994). It shows effectiveness for the treatment of type I allergy-related diseases such as bronchial asthma, allergic rhinitis urticaria and similar maladies (Satoh et al, 2003;Taniguchi et al, 1996). After oral administration, suplatast tosilate is metabolized to 4-(3-ethoxy-2-hydroxypropoxy) acrylanilide (M-1) by alkaline hydrolysis, and the in vivo effect of this drug is mainly due to the action of this metabolite (Keizo and Dotai, 1992).…”

Section: Introductionmentioning

confidence: 99%

Liquid chromatography/electrospray ionization mass spectrometry method for the determination of the active metabolite M‐1 of suplatast tosilate in human plasma

Ding

Zhou

et al. 2007

Biomedical Chromatography

View full text Add to dashboard Cite

A liquid chromatography/electrospray ionization mass spectrometry (LC/ESIMS) method for the determination of 4-(3-ethoxy-2-hydroxypropoxy) acrylanilide (M-1), the active metabolite of suplatast tosilate, in human plasma was established. Plasma samples were extracted with diethyl ether, separated on a C(18) column with a mobile phase of acetonitrile-10 mm ammonium acetate solution containing 0.1% formic acid (28:72, v/v) and detected by ESIMS. The method was linear over the concentration range 0.15-60.0 ng/mL. The lowest limit of quantification was 0.15 ng/mL. The intra- and inter-run relative standard deviations obtained from three validation runs were all less than 8.6%, and the intra- and inter-run relative errors were all less than 3.1%. The method was successfully applied for the evaluation of pharmacokinetic profiles of M-1 in healthy volunteers.

show abstract

Section: Introductionmentioning

confidence: 99%

Liquid chromatography/electrospray ionization mass spectrometry method for the determination of the active metabolite M‐1 of suplatast tosilate in human plasma

Ding

Zhou

et al. 2007

Biomedical Chromatography

View full text Add to dashboard Cite

show abstract

“…However, the degree or nature of airway inflammation was not evaluated in the report. Taniguchi et al [15]also demonstrated that IPD could inhibit BHR to acetylcholine in a guinea pig model of asthma, in which the animal was sensitized twice and challenged once with aerosolized OVA. Although specific IgE was not detected in this model, eosinophils in BALF and in peribronchioles were significantly decreased to about half and one third, respectively, by IPD treatment of 100 mg/kg/day.…”

Section: Discussionmentioning

confidence: 99%

“…In the treated group (IPD group), IPD (100 mg/kg/100 µl) was orally given to mice once a day for 21 days (days 0–20). The dose was determined by previous reports showing obvious inhibition of IgE synthesis [14, 15]. In the positive control group (OVA control group), saline alone was used instead of the compound.…”

Section: Methodsmentioning

confidence: 99%

“…Therefore, this compound would be effective at least in the murine model of asthma. However, there are a few studies concerning the effectiveness of IPD on animal models [14, 15]. Therefore, we performed this study to elucidate the effect of IPD on a mouse model of asthma, in terms of airway inflammation, production of specific antibodies, BHR to methacholine (MCh), and local production of cytokines.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of Suplatast Tosilate (IPD-1151T) on a Mouse Model of Asthma: Inhibition of Eosinophilic Inflammation and Bronchial Hyperresponsiveness

Zhao

Yokoyama²,

Kohno³

et al. 2000

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: Suplatast tosilate (IPD) is a newly developed ‘anti-allergic’ drug. It seems to be a unique compound because of its ability to suppress IgE but not IgG or IgM production in vivo and cytokine production from type 2 helper T cells (Th2) in vitro. However, information on its in vivo effect on an animal model of asthma is limited. Method: BALB/c mice sensitized to ovalbumin (3 times, 2-week interval) were challenged with ovalbumin by inhalation (50 mg/ml for 20 min, once a day for 6 days). In this study, we explored the influence of IPD on eosinophil infiltration into the airways, bronchial hyperresponsiveness (BHR) to methacholine, specific IgE antibody production, and cytokines in bronchoalveolar lavage fluid (BALF) using this murine model. Results: Treatment with IPD significantly reduced the number of total cells and eosinophils in BALF (around –40%) and almost completely inhibited the development of antigen-induced BHR. Histological findings confirmed the reduction of submucosal cell infiltration in the lung, and disclosed the marked inhibition of bronchial epithelial cell damage. Ovalbumin-specific IgE was slightly but significantly reduced. The levels of IL-4, IL-5 and IL-13 in BALF were significantly decreased in mice treated with the compound compared to those in untreated mice. Conclusion: These results suggest that IPD is capable of inhibiting the production of Th2 cytokines, which inhibit eosinophil infiltration into the murine airway, IgE synthesis, and development of BHR, in a murine model of asthma.

show abstract

“…Recently, IL-5, which is derived from Th2 cells, has been shown to play an important role in the development of eosinophil infiltration [17 -20]. Suplatast has been reported to inhibit IL-5 production by Th2 cells [13] and antigeninduced eosinophil infiltration into the lung and the skin [21,22]. Thus, inhibition of the LPR by suplatast is due to the suppression of eosinophil infiltration, accompanied by its suppressive effects on IL-5 production.…”

Section: Effects Of Oral Administration Of Drugs On the Lpr In Balb/cmentioning

confidence: 99%

Effect of Y-24180, a receptor antagonist to platelet-activating factor (PAF), on allergic cutaneous reactions in actively sensitized mice

Yamaguchi¹,

Tomomatsu²,

Komatsu³

2000

Inflammation Research

View full text Add to dashboard Cite

show abstract

Suplatast tosilate, a new type of antiallergic agent, prevents the expression of airway hyperresponsiveness in guinea pigs

Cited by 19 publications

References 18 publications

Liquid chromatography/electrospray ionization mass spectrometry method for the determination of the active metabolite M‐1 of suplatast tosilate in human plasma

Liquid chromatography/electrospray ionization mass spectrometry method for the determination of the active metabolite M‐1 of suplatast tosilate in human plasma

Effect of Suplatast Tosilate (IPD-1151T) on a Mouse Model of Asthma: Inhibition of Eosinophilic Inflammation and Bronchial Hyperresponsiveness

Effect of Y-24180, a receptor antagonist to platelet-activating factor (PAF), on allergic cutaneous reactions in actively sensitized mice

Contact Info

Product

Resources

About